FR2674753B1 - Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables. - Google Patents

Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.

Info

Publication number
FR2674753B1
FR2674753B1 FR9104218A FR9104218A FR2674753B1 FR 2674753 B1 FR2674753 B1 FR 2674753B1 FR 9104218 A FR9104218 A FR 9104218A FR 9104218 A FR9104218 A FR 9104218A FR 2674753 B1 FR2674753 B1 FR 2674753B1
Authority
FR
France
Prior art keywords
denimous
contraindications
aids
molecule
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9104218A
Other languages
English (en)
Other versions
FR2674753A1 (fr
Inventor
Jean Berque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9104218A priority Critical patent/FR2674753B1/fr
Application filed by Individual filed Critical Individual
Priority to EP92909405A priority patent/EP0578733A1/fr
Priority to CA002107078A priority patent/CA2107078A1/fr
Priority to AU16540/92A priority patent/AU1654092A/en
Priority to JP4508599A priority patent/JPH06506212A/ja
Priority to PCT/FR1992/000296 priority patent/WO1992017173A2/fr
Publication of FR2674753A1 publication Critical patent/FR2674753A1/fr
Priority to OA60422A priority patent/OA09819A/fr
Priority to FR9414656A priority patent/FR2715303A1/fr
Application granted granted Critical
Publication of FR2674753B1 publication Critical patent/FR2674753B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9104218A 1991-04-02 1991-04-02 Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables. Expired - Fee Related FR2674753B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR9104218A FR2674753B1 (fr) 1991-04-02 1991-04-02 Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
CA002107078A CA2107078A1 (fr) 1991-04-02 1992-04-02 Utilisation de la riboflavine dans le traitement de maladies liees aux virus vih, de l'herpes, de la retinite pigmentaire et du paludisme
AU16540/92A AU1654092A (en) 1991-04-02 1992-04-02 Use of riboflavin for treating hiv-related diseases, herpes, retinitis pigmentosa and malaria
JP4508599A JPH06506212A (ja) 1991-04-02 1992-04-02 Ｈｉｖウイルス系疾病、ヘルペス、色素性網膜炎およびマラリアの治療向けリボフラビンの利用
EP92909405A EP0578733A1 (fr) 1991-04-02 1992-04-02 Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme
PCT/FR1992/000296 WO1992017173A2 (fr) 1991-04-02 1992-04-02 Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme
OA60422A OA09819A (fr) 1991-04-02 1993-10-01 Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme
FR9414656A FR2715303A1 (fr) 1991-04-02 1994-12-06 Utilisation du FAD et/ou du NAD comme médicaments.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9104218A FR2674753B1 (fr) 1991-04-02 1991-04-02 Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.

Publications (2)

Publication Number Publication Date
FR2674753A1 FR2674753A1 (fr) 1992-10-09
FR2674753B1 true FR2674753B1 (fr) 1995-03-10

Family

ID=9411559

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9104218A Expired - Fee Related FR2674753B1 (fr) 1991-04-02 1991-04-02 Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.

Country Status (7)

Country Link
EP (1) EP0578733A1 (fr)
JP (1) JPH06506212A (fr)
AU (1) AU1654092A (fr)
CA (1) CA2107078A1 (fr)
FR (1) FR2674753B1 (fr)
OA (1) OA09819A (fr)
WO (1) WO1992017173A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US7901673B2 (en) 2000-06-02 2011-03-08 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
DK0643775T3 (da) * 1992-05-28 2004-09-06 Ct For Molecular Biology And M Quinonderivater til forbedring af cellebioenergi
FR2696319B1 (fr) * 1992-10-02 1994-12-30 Jean Berque Utilisation de produits biologiques atoxiques et principalement de la riboflavine dans la fabrication des préservatifs et des gants de protection médico-chirurgicaux.
GB9321558D0 (en) * 1993-10-19 1993-12-08 Radopath Ltd Anti-viral agents
GB2319474A (en) * 1993-10-19 1998-05-27 Radopath Ltd Anti-viral agents
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US6548241B1 (en) 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
WO2002074313A1 (fr) * 2001-03-21 2002-09-26 Eisai Co., Ltd. Médicaments à base de vitamine b2 réduite

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2096712A1 (en) * 1970-06-29 1972-02-25 Giraux Georges Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders
GB1431841A (en) * 1973-01-15 1976-04-14 Evans S C Ophthalmic-nutritional preparations
DE2559569A1 (de) * 1975-10-22 1977-04-28 Josef Hofmann Fluessiges futtermittel fuer brieftauben
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
JPS59172417A (ja) * 1983-03-23 1984-09-29 Nisshin Kagaku Kk リボフラビン酪酸エステル含有軟カプセル
JPS61275228A (ja) * 1985-03-14 1986-12-05 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド 治療用タンパク組成物中のビ−ルスの光動的不活性化
DE3542309A1 (de) * 1985-11-29 1987-06-04 Cardona Federico Dr Medizinisches antioxidativum
EP0494992A4 (en) * 1989-10-06 1993-03-31 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
CA2068427A1 (fr) * 1989-11-09 1991-05-10 Patricia A. Agin Riboflavine en tant que stimulateur du bronzage

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6828323B2 (en) 1999-10-19 2004-12-07 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US7892535B2 (en) 2000-06-02 2011-02-22 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US7901673B2 (en) 2000-06-02 2011-03-08 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light

Also Published As

Publication number Publication date
FR2674753A1 (fr) 1992-10-09
EP0578733A1 (fr) 1994-01-19
AU1654092A (en) 1992-11-02
OA09819A (fr) 1994-04-15
JPH06506212A (ja) 1994-07-14
WO1992017173A2 (fr) 1992-10-15
WO1992017173A3 (fr) 1993-01-07
CA2107078A1 (fr) 1992-10-03

Similar Documents

Publication Publication Date Title
FR2674753B1 (fr) Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
FR2710541B1 (fr) Ensemble pour l'introduction d'un cathéter.
MA26420A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
GB9503601D0 (en) Method of treatment and method of manufacture of medicament
FR2720002B1 (fr) Dispositif d'incision pour l'administration dermique d'un médicament.
TR199600786T1 (tr) Agiz yoluyla alinan yeni farmasötik dozaj formlari.
FR2698780B1 (fr) Catheter pour le traitement d'un tissu pathologique.
FR2714594B3 (fr) Structure de diffuseur pour infusion de plantes médicinales.
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
MA26779A1 (fr) Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
FR2688405B1 (fr) Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant.
MA24339A1 (fr) Procede de preparation de medicaments destines au traitement d'infections bacteriennes en pediaterie
MA26658A1 (fr) Derivés de valérohydrazine, procédé pour les préparer, médicament pour le traitement des maladies inflammatoires et auto-immunes les contenant, et leur utilisation pour préparer un tel médicament
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
FR2697754B1 (fr) Procédé et machine pour le traitement de déchets médicaux.
ZA925146B (en) Pharmaceutical agent for treatment of withdrawal symptoms.
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
FR2658419B1 (fr) Medicament pour le traitement de la dermatite.
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
FR2716623B1 (fr) Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs.
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20101230